论文部分内容阅读
目的探讨地特胰岛素注射液合瑞格列奈治疗2型糖尿病临床疗效及安全性。方法 60例2型糖尿病患者,随机分为治疗组(30例)和对照组(30例)。治疗组采用三餐前口服瑞格列奈,睡前固定时间皮下肌肉注射地特胰岛素;对照组早、晚餐前30 min皮下注射预混胰岛素。两组患者治疗期间均根据血糖调整用药剂量,观察两组空腹血糖(FPG)及餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)、体质量变化、胰岛素用量、尿素氮、肌酐及低血糖发生情况。结果两组患者FPG、2 h PG、HbA1c较治疗前明显下降(P<0.05),观察组胰岛素用量、低血糖发生率较对照组低(P<0.05),观察组HbA1c控制优于对照组(P<0.05),尿素氮、肌酐差异无统计学意义(P>0.05)。结论地特胰岛素联合瑞格列奈治疗糖尿病,患者依从性好,低血糖发生率低,疗效确切。
Objective To investigate the clinical efficacy and safety of insulin detemir injection and repaglinide in type 2 diabetes mellitus. Methods Sixty patients with type 2 diabetes were randomly divided into treatment group (30 cases) and control group (30 cases). In the treatment group, oral repaglinide was given before the three meals a day, and insulin was injected subcutaneously at a fixed time before bedtime. In the control group, premixed insulin was injected subcutaneously 30 minutes before breakfast and dinner. During the treatment period, the fasting blood glucose (FPG) and 2 h PG, HbA1c, body weight, insulin dosage, urea nitrogen, creatinine, Hypoglycemia occurs. Results The FPG, 2 h PG and HbA1c in two groups were significantly lower than those before treatment (P <0.05). The insulin dosage and the incidence of hypoglycemia in the observation group were lower than those in the control group (P <0.05). HbA1c control in the observation group was better than that in the control group P <0.05). There was no significant difference between urea nitrogen and creatinine (P> 0.05). Conclusions Dextrins combined with repaglinide in the treatment of diabetes patients with good compliance, low incidence of hypoglycemia, the exact effect.